ALK-Abelló 향후 성장
Future 기준 점검 3/6
ALK-Abelló (는) 각각 연간 15% 및 12.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 15% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 19.8% 로 예상됩니다.
핵심 정보
15.0%
이익 성장률
15.03%
EPS 성장률
| Pharmaceuticals 이익 성장 | 10.7% |
| 매출 성장률 | 12.3% |
| 향후 자기자본이익률 | 19.80% |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 05 May 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Apr 24
ALK B: Future Upside Will Come From Needle Free Anaphylaxis Treatment Adoption
Analysts have nudged their price target for ALK-Abelló to DKK 263.33 from DKK 255, reflecting updated assumptions around slightly adjusted revenue growth, profit margin expectations, and a higher future P/E multiple. What's in the News ALK reported positive topline phase 2 data from the ALLIANCE trial of its once daily sublingual immunotherapy tablet for peanut allergy in patients aged 4 to 65 years, with statistically significant, dose dependent efficacy across multiple tolerated dose and eliciting dose endpoints and a safety profile without treatment related anaphylaxis or serious adverse events (Key Developments).내러티브 업데이트 • Apr 09
ALK B: Future Upside Will Come From Wider Needle Free Anaphylaxis Treatment Adoption
Analysts have adjusted their DKK price targets for ALK-Abelló to reflect updated assumptions for revenue growth of 13.31%, profit margin of 20.66% and a future P/E of 34.79. This suggests a modest recalibration in how the company’s earnings power is being valued.내러티브 업데이트 • Mar 25
ALK B: Future Upside Will Rely On Wider Anaphylaxis Spray Adoption
Analysts have kept their DKK price target for ALK-Abelló broadly unchanged at DKK 255, reflecting stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This signals a steady view on the company’s outlook.내러티브 업데이트 • Mar 11
ALK B: Future Upside Will Rely On Wider Anaphylaxis Treatment Adoption
Analysts have kept their DKK 255.00 price target for ALK-Abelló unchanged, indicating that their views on fair value, discount rate, expected revenue growth, profit margin and future P/E assumptions remain broadly steady. What's in the News ALK-Abelló presented late-breaking data from a 90-participant study comparing needle-free EURneffy nasal adrenaline to injectable auto-injectors for anaphylaxis, with 88% of participants preferring EURneffy, mainly for ease of use, portability and the absence of a needle (AAAAI 2026 Annual Meeting).내러티브 업데이트 • Feb 25
ALK B: Future Returns Will Rely On Expanded Anaphylaxis Indications And Stronger Margins
Analysts have nudged their price target on ALK-Abelló up from DKK 249 to DKK 255, reflecting updated assumptions that combine slightly lower expected revenue growth with a higher projected profit margin and a modestly lower future P/E multiple. What's in the News ALK Abelló issued earnings guidance for 2026, indicating an expectation of continued double digit revenue growth and higher earnings, with revenue projected to grow 11 to 15% in local currencies (company guidance).내러티브 업데이트 • Feb 10
ALK B: Future Returns Will Rely On Expanded Anaphylaxis Reach And Higher 2025 Margins
Analysts have lifted their fair value estimate for ALK-Abelló from DKK 214 to DKK 249, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending EU marketing authorisation for EURneffy 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children aged 4 years and older weighing 15 kg to 30 kg.내러티브 업데이트 • Jan 27
ALK B: Future Returns Will Reflect Upgraded 2025 Outlook And Stable Margin Ambitions
Analysts have kept their price target for ALK-Abelló steady at DKK 214. This reflects unchanged assumptions around discount rate, revenue growth, profit margin and future P/E, and indicates that new research has not materially shifted their valuation view.
새로운 내러티브 • Jan 23
Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity
Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?분석 기사 • Jan 23
ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...내러티브 업데이트 • Jan 12
ALK B: Future Returns Will Reflect Upgraded Outlook And Balanced Margin Prospects
Analysts have trimmed their price target for ALK-Abelló to €214.00 from €219.33, citing updated assumptions that now reflect slightly higher revenue growth, a modestly lower profit margin outlook and a small adjustment to the projected future P/E multiple. What's in the News ALK-Abelló upgraded its earnings guidance for the full year 2025, with expected revenue growth of 13% to 15% in local currencies, compared with a previous range of 12% to 14% (Key Developments).내러티브 업데이트 • Dec 19
ALK B: Future Returns Will Reflect Upgraded Outlook And Solid Margin Prospects
Analysts have modestly lifted their average price target on ALK-Abelló to DKK 219.33, reflecting steady confidence in the company’s unchanged long term growth, margin, and valuation assumptions despite minimal adjustments to underlying model inputs. What's in the News Upgraded 2025 revenue guidance to 13% to 15% growth in local currencies, from 12% to 14%, supported by stronger demand across all regions and product lines (company guidance).분석 기사 • Dec 08
Investors Appear Satisfied With ALK-Abelló A/S' (CPH:ALK B) Prospects
With a price-to-earnings (or "P/E") ratio of 45.8x ALK-Abelló A/S ( CPH:ALK B ) may be sending very bearish signals at...내러티브 업데이트 • Dec 05
ALK B: Future Returns Will Reflect China Alliance And Margin Outlook
Analysts have maintained their DKK 219.33 price target for ALK Abelló, reflecting stable expectations for sustained double digit revenue growth, robust profit margins and a premium future P E multiple. What's in the News Upgraded 2025 guidance, with expected revenue growth raised to 13% to 15% in local currencies, supported by higher treatment volumes across allergy immunotherapy and anaphylaxis products, and an improved projected EBIT margin of about 26% (company guidance).내러티브 업데이트 • Nov 21
ALK B: Improved Margins and China Partnership Will Drive Steady Outlook
Analysts have raised their price target for ALK-Abelló to DKK 219.33 from DKK 196.00. They cite ongoing improvements in profit margins and a slightly higher projected fair value as the reasons for the adjustment.분석 기사 • Nov 15
ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets
It's been a pretty great week for ALK-Abelló A/S ( CPH:ALK B ) shareholders, with its shares surging 15% to kr.230 in...내러티브 업데이트 • Nov 04
ALK B: Chinese Partnership And Revenue Upside Will Drive Future Opportunities
Analysts have raised their price target for ALK-Abelló from DKK 193 to DKK 196. This change is based on slightly improved revenue growth estimates and valuation adjustments.분석 기사 • Oct 11
Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...내러티브 업데이트 • Aug 23
Allergy+ Strategy Will Reach Millions With New Therapies
The increase in ALK-Abelló’s analyst price target is primarily driven by a modest upward revision in consensus revenue growth forecasts, while net profit margins remain steady, resulting in a new fair value estimate of DKK192.33 per share. What's in the News ALK-Abelló raised its 2025 revenue growth guidance to 12-14% (from 9-13%) in local currencies, supported by strong adrenaline autoinjector and tablet sales in Europe and North America, and will allocate additional funds to strategic growth investments.분석 기사 • Jul 23
ALK-Abelló A/S' (CPH:ALK B) Popularity With Investors Is Clear
With a price-to-earnings (or "P/E") ratio of 44.9x ALK-Abelló A/S ( CPH:ALK B ) may be sending very bearish signals at...분석 기사 • Jun 17
ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
새로운 내러티브 • Dec 11
Allergy+ Strategy And Neffy Nasal Spray Will Ignite Revenue Growth And Boost Earnings
The Allergy+ strategy and neffy nasal spray deal are expected to create new revenue streams and drive growth from 2025 onward.이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 9,330 | 1,862 | 1,427 | 1,861 | 4 |
| 12/31/2027 | 8,257 | 1,639 | 1,223 | 1,667 | 4 |
| 12/31/2026 | 7,277 | 1,444 | 1,051 | 1,512 | 4 |
| 3/31/2026 | 6,561 | 1,280 | 1,796 | 2,189 | N/A |
| 12/31/2025 | 6,312 | 1,197 | 1,457 | 1,817 | N/A |
| 9/30/2025 | 6,078 | 1,101 | 218 | 1,548 | N/A |
| 6/30/2025 | 5,861 | 999 | 70 | 1,380 | N/A |
| 3/31/2025 | 5,708 | 937 | 18 | 1,319 | N/A |
| 12/31/2024 | 5,537 | 815 | -90 | 1,213 | N/A |
| 9/30/2024 | 5,383 | 785 | 777 | 1,086 | N/A |
| 6/30/2024 | 5,180 | 690 | 724 | 1,046 | N/A |
| 3/31/2024 | 4,941 | 555 | 449 | 796 | N/A |
| 12/31/2023 | 4,824 | 486 | 288 | 667 | N/A |
| 9/30/2023 | 4,728 | 424 | 17 | 426 | N/A |
| 6/30/2023 | 4,680 | 359 | -76 | 343 | N/A |
| 3/31/2023 | 4,590 | 335 | 90 | 479 | N/A |
| 12/31/2022 | 4,511 | 335 | 63 | 416 | N/A |
| 9/30/2022 | 4,361 | 333 | 149 | 489 | N/A |
| 6/30/2022 | 4,227 | 318 | 163 | 493 | N/A |
| 3/31/2022 | 4,050 | 255 | 152 | 432 | N/A |
| 12/31/2021 | 3,916 | 219 | 205 | 468 | N/A |
| 9/30/2021 | 3,808 | 112 | 273 | 505 | N/A |
| 6/30/2021 | 3,652 | 55 | 158 | 358 | N/A |
| 3/31/2021 | 3,556 | 66 | 147 | 358 | N/A |
| 12/31/2020 | 3,491 | 25 | 79 | 301 | N/A |
| 9/30/2020 | 3,383 | 43 | 87 | 298 | N/A |
| 6/30/2020 | 3,350 | 49 | 149 | 353 | N/A |
| 3/31/2020 | 3,363 | -9 | -14 | 172 | N/A |
| 12/31/2019 | 3,274 | -50 | N/A | 132 | N/A |
| 9/30/2019 | 3,178 | -183 | N/A | 59 | N/A |
| 6/30/2019 | 3,100 | -200 | N/A | -54 | N/A |
| 3/31/2019 | 3,030 | -149 | N/A | -27 | N/A |
| 12/31/2018 | 2,915 | -170 | N/A | -95 | N/A |
| 9/30/2018 | 2,891 | -183 | N/A | -223 | N/A |
| 6/30/2018 | 2,897 | -152 | N/A | -214 | N/A |
| 3/31/2018 | 2,873 | -136 | N/A | -386 | N/A |
| 12/31/2017 | 2,910 | -158 | N/A | -387 | N/A |
| 9/30/2017 | 2,901 | 37 | N/A | -278 | N/A |
| 6/30/2017 | 2,864 | 76 | N/A | -146 | N/A |
| 3/31/2017 | 2,946 | 149 | N/A | 206 | N/A |
| 12/31/2016 | 3,005 | 270 | N/A | 405 | N/A |
| 9/30/2016 | 2,938 | 373 | N/A | 492 | N/A |
| 6/30/2016 | 2,975 | 396 | N/A | 458 | N/A |
| 3/31/2016 | 2,767 | 378 | N/A | 312 | N/A |
| 12/31/2015 | 2,569 | 344 | N/A | 183 | N/A |
| 9/30/2015 | 2,494 | 221 | N/A | 153 | N/A |
| 6/30/2015 | 2,349 | 185 | N/A | 136 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: ALK B 의 연간 예상 수익 증가율(15%)이 saving rate(2%)보다 높습니다.
수익 vs 시장: ALK B 의 연간 수익(15%)이 Danish 시장(9.2%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 수익: ALK B 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.
수익 대 시장: ALK B 의 수익(연간 12.3%)이 Danish 시장(연간 3.8%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: ALK B 의 수익(연간 12.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: ALK B의 자본 수익률은 3년 후 19.8%로 낮을 것으로 예상됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 11:42 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
ALK-Abelló A/S는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | ABG Sundal Collier |
| Jesper Ilsoe | Carnegie Investment Bank AB |
| Jesper Ingildsen | DNB Carnegie |